Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation

Summary

To investigate safety of treatment with allogeneic adipose tissue-derived mesenchymal stromal cells (ASCs) in patients undergoing lung transplantation, to evaluate whether the treatment can reduce host immunological reaction towards the graft, and to reduce the ischemic reperfusion-injury after transplantation.

Timeline

Start

2020-10-01

Primary completion

2023-11-30

Completion

2024-11-30

Publications

• Qayyum AA, Lund TK, Jensen PB, Jensen K, Haack-Sorensen M, Ekblond A, Norgaard MJ, Moller-Sorensen H, Mathiasen AB, Moller CH, Rorvig SB, Kalhauge A, Bruunsgaard H, Litman T, Johansen EM, Hojgaard LD, Kastrup J, Perch M. Allogeneic mesenchymal stromal cell therapy on primary graft dysfunction after lung transplantation. JHLT Open. 2025 Mar 20;8:100254. doi: 10.1016/j.jhlto.2025.100254. eCollection 2025 May.

Drugs

Indications